LIFECORE BIOMEDICAL, INC. \DE\ — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Lifecore reported Q3 2026 revenues of $25.3M (down 18.6% YoY from $31.1M); nine-month revenues $82.7M (down 21.8% YoY from $105.7M). Net loss widened to $40.1M in Q3 ($1.08/share) versus $10.0M in Q3 2025 ($0.29/share), driven by $31.3M change in fair value of related-party debt derivative. CDMO segment declined 29% YoY for nine months ($49.1M vs $69.4M). Company ended Q3 with $38.0M liquidity ($23.0M cash, $15.0M credit availability) and is pending completion of proposed merger with Hazel Merger Sub per agreement dated September 27, 2026.
Why this rating
Large revenue decline (22% YoY) and widening losses material to $223M company; pending merger creates execution risk and management distraction; offsetting factor: new business wins signal pipeline recovery starting 2027.
Price action (we called it negative)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.